Braslis K G, Fletcher D R, Shulkes A, Scoggins B A, Tresham J, Hardy K J
Department of Surgery, University of Melbourne, Austin Hospital, Heidelberg, Australia.
J Hypertens. 1988 Nov;6(11):881-7. doi: 10.1097/00004872-198811000-00006.
Calcitonin gene-related peptide (CGRP) is localized in nerve fibres in close association with the vasculature. The in vivo effect of human CGRP upon the cardiovascular system was investigated by intravenous infusion of CGRP into seven conscious sheep at doses of 1.5 and 10-pmol/kg per min for 75 min. CGRP at the 5- and 10-pmol/kg per min infusions decreased mean arterial pressure (maximal decrease of 10 mmHg) and stroke volume (maximal decrease of 42 ml/min), and increased heart rate by 60 beats/min. No changes in cardiac output were observed and total peripheral resistance only fell with the 5-pmol/kg per min infusion. Increases in both plasma arginine vasopressin and plasma renin concentration and a decrease in total and ionized plasma calcium were also observed. CGRP appears to be a potent vasodilator acting upon both arterioles and capacitance vessels in vivo.
降钙素基因相关肽（CGRP）定位于与脉管系统紧密相连的神经纤维中。通过以每分钟1.5和10皮摩尔/千克的剂量向7只清醒绵羊静脉输注CGRP 75分钟，研究了人CGRP对心血管系统的体内作用。以每分钟5和10皮摩尔/千克的剂量输注CGRP可降低平均动脉压（最大降幅为10 mmHg）和每搏输出量（最大降幅为42毫升/分钟），并使心率增加60次/分钟。未观察到心输出量的变化，仅在以每分钟5皮摩尔/千克的剂量输注时总外周阻力下降。还观察到血浆精氨酸加压素和血浆肾素浓度均升高，以及血浆总钙和离子钙降低。CGRP似乎是一种强效血管舒张剂，在体内对小动脉和容量血管均起作用。
